NCT05485584View on ClinicalTrials.gov

rSIFN-co Among Healthy Subjects and Subjects With Mild or Asymptomatic COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

188

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

April 5, 2023

Study Completion Date

April 5, 2023

Conditions
COVID-19SARS-CoV-2 Infection
Interventions
DRUG

rSIFN-co Nasal Spray

8 million IU (16 μg)/day; Once daily

DRUG

rSIFN-co Nasal Spray

16 million IU (32 μg)/day; Twice daily

DRUG

Placebo Nasal Spray

Once daily

DRUG

Placebo Nasal Spray

Twice daily

Trial Locations (2)

Unknown

GreenCity Medical Center, San Fernando City

Medical Center Manila, Manila

All Listed Sponsors
lead

Sichuan Huiyang Life Science and Technology Corporation

INDUSTRY